On May 1, the US Food and Drug Administration approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) for adult patients with newly diagnosed or relapsed/refractory multiple myeloma, marking the first approval for this innovative subcutaneous formulation globally and providing a must faster form of administration.
This new product, from US healthcare giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Biotech, allows for subcutaneous dosing of daratumumab, marketed as Darzalex. J&J’s shares closed up 1.12% at $148.29 on Friday.
Janssen was granted an exclusive worldwide license to develop, manufacture and commercialize daratumumab by Denmark’s Genmab (Nasdaq: GMAB) in August 2012. Darzalex is already a blockbuster seller for the US company, having generated first quarter 2020 sales of $937 million, up 49% from the like, 2019 quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze